Inotrem is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.
Inotrem identified the TREM-1 pathway as a key factor causing unbalanced inflammatory responses. The company focuses on the therapeutic tools derived from knowledge of the biology of TREM-1 pathway.
Through its proprietary technology platform, Inotrem has developed the first-in-class clinical TREM-1 inhibitor, nangibotide (LR12), with applications in a number of indications such as septic shock or myocardial infarction.
INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.
A first clinical trial to assess the safety, tolerability and pharmacokinetics of MOTREM in healthy volunteers is currently ongoing.
Intensive Care Medicine publishes the results of Inotrem’s study which demonstrated the safety and tolerability of its lead compound, nangibotide, in patients suffering from septic shock.
Intensive Care Medicine publishes the results of Inotrem’s study which demonstrated the safety and tolerability of its lead compound, nangibotide, in patients suffering from septic shock.
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices